Page 55 - HIV/AIDS Guidelines

33. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the
impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. Oct 1 2008;22(15):1979-1991.
34. Thio CL, Seaberg EC, Skolasky R, Jr., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the
Multicenter Cohort Study (MACS). Lancet. Dec 14 2002;360(9349):1921-1926.
35. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency
virus: the D:A:D study. Arch Intern Med. Aug 14-28 2006;166(15):1632-1641.
36. Balagopal A, Philp FH, Astemborski J, et al. Human immunodeficiency virus-related microbial translocation and
progression of hepatitis C. Gastroenterology. Jul 2008;135(1):226-233.
37. Blackard JT, Kang M, St Clair JB, et al. Viral factors associated with cytokine expression during HCV/HIV co-infection.
J Interferon Cytokine Res. Apr 2007;27(4):263-269.
38. Hong F, Tuyama A, Lee TF, et al. Hepatic stellate cells express functional CXCR4: role in stromal cell-derived factor-
1alpha-mediated stellate cell activation. Hepatology. Jun 2009;49(6):2055-2067.
39. Macias J, Berenguer J, Japon MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected
with human immunodeficiency virus/hepatitis C virus. Hepatology. Oct 2009;50(4):1056-1063.
40. Verma S, Goldin RD, Main J. Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection: is it associated with
antiretroviral therapy and more advanced hepatic fibrosis? BMC Res Notes. 2008;1:46.
41. Ragni MV, Nalesnik MA, Schillo R, Dang Q. Highly active antiretroviral therapy improves ESLD-free survival in HIV-
HCV co-infection. Haemophilia. Mar 2009;15(2):552-558.
42. Matthews GV, Avihingsanon A, Lewin SR, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV
coinfected antiretroviral naive individuals in Thailand. Hepatology. Oct 2008;48(4):1062-1069.
43. Peters MG, Andersen J, Lynch P, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B
virus and HIV infection: ACTG A5127. Hepatology. Nov 2006;44(5):1110-1116.
44. Avidan NU, Goldstein D, Rozenberg L, et al. Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in
HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts. J Acquir Immune Defic Syndr. Dec 1
2009;52(4):452-458.
45. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced
patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Lancet. Apr 7 2007;369(9568):1169-1178.
46. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1
infection. N Engl J Med. Jul 24 2008;359(4):339-354.
47. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily
lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-
infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr. Mar 1
2010;53(3):323-332.

48. van Leth F, Andrews S, Grinsztejn B, et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy
and safety of nevirapine or efavirenz-based first-line HAART. AIDS. Mar 25 2005;19(5):463-471.

49. Smith C. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS.
Jun 19 2010;24(10):1537-1548.

50. Mocroft A, Reiss P, Gasiorowski J, et al. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir
Immune Defic Syndr. Oct 1 2010;55(2):262-270.

51. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction
in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. Apr 26 2008;371(9622):1417-
1426.

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents E-14

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.